ArticleFrontiers in ophthalmology2024
Unexpected retinal fluid compartment responses with anti-VEGF therapy in polypoidal choroidal vasculopathy: a case report of four patients.
Article in Frontiers in ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg.Ophthalmology and therapy · 2026Review
- Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.Ophthalmology and therapy · 2026Article
- Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case series describes responses to faricimab treatment in opposite directions in different fluid compartments in four patients with polypoidal choroidal vasculopathy (PCV). Despite reductions in retinal fluid (SRF) and stable visual acuity following treatment, all patients developed retinal pigment epithelium (RPE) elevation. Over a 12-15 months follow-up, three patients exhibited a gradual decrease in RPE elevation, with one case resolving completely. These findings suggest that fluid compartments in PCV may respond differently to treatment and add to the understanding of PCV by highlighting the complex interplay between different retinal fluid compartments in response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.